Peggy Hours-Zesiger

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

Uwe Reuter, Peter J. Goadsby, Michel Lantéri‐Minet et al. · The Lancet · 2018 · 470 citations · Full text

Medicine, Neurology, Pharmacology +9

Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial

Uwe Reuter, Marc Ehrlich, Astrid Gendolla et al. · Cephalalgia · 2021 · 178 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study

Shuu‐Jiun Wang, Artemio Roxas, B. Saravia et al. · Cephalalgia · 2021 · 65 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Long-term Efficacy and Safety of Erenumab

Peter J. Goadsby, Uwe Reuter, Michel Lantéri‐Minet et al. · Neurology · 2021 · 50 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY study

Michel Lantéri‐Minet, Peter J. Goadsby, Uwe Reuter et al. · Journal of Neurology Neurosurgery & Psychiatry · 2021 · 25 citations · Full text

Pharmacy, Pharmacotherapy, Cost-effectiveness Analysis +16